Targeting the interleukin-6/Jak/stat pathway in human malignancies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22355058.
- Also identified by DOI 10.1200/JCO.2010.31.8907 and PMC identifier 3341105.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling. Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies. Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6-mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis. This transcription factor regulates the expression of numerous critical mediators of tumor formation and metastatic progression. This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.
Medical subject headings
- Antineoplastic Agents
- Janus Kinases
- Neoplasms
- STAT Transcription Factors
- Signal Transduction
- Interleukin-6 Inhibitors